Functionally significant proteins expressed by tumor macrophages have emerged as promising anti-cancer targets. In this issue of Cancer Cell, Sun et al. identify two FDA-approved agents that together safely reprogram tumor macrophages into potent anti-tumor effectors, demonstrating the power of engaging both immune system arms to fight cancer.
|Original language||English (US)|
|Number of pages||3|
|State||Published - Oct 11 2021|
ASJC Scopus subject areas
- Cell Biology
- Cancer Research